FR11C0002I2 - POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT - Google Patents
POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUTInfo
- Publication number
- FR11C0002I2 FR11C0002I2 FR11C0002C FR11C0002C FR11C0002I2 FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2 FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 C FR11C0002 C FR 11C0002C FR 11C0002 I2 FR11C0002 I2 FR 11C0002I2
- Authority
- FR
- France
- Prior art keywords
- pct
- person
- narrowing
- asthma
- susceptibility
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- External Artificial Organs (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Seasonings (AREA)
Abstract
PCT No. PCT/AU95/00086 Sec. 371 Date Nov. 4, 1996 Sec. 102(e) Date Nov. 4, 1996 PCT Filed Feb. 23, 1995 PCT Pub. No. WO95/22993 PCT Pub. Date Aug. 31, 1995A method as described for testing the susceptibility of a person to asthma. The person inhales an effective amount of sodium chloride, mannitol or another substance capable of altering the osmolarity of airway surface liquid in the subject. The substance is in the form of a dispersible dry powder containing an effective proportion of particles of a respirable size. The subject is then measured to detect airway narrowing which is indicative of a propensity for asthma. The same technique of dry powder inhalation can be used to test for the susceptibility of a person to rhinitus, to induce sputum and promote mucociliary clearance.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPM4114A AUPM411494A0 (en) | 1994-02-25 | 1994-02-25 | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
PCT/AU1995/000086 WO1995022993A1 (en) | 1994-02-25 | 1995-02-23 | Method and device for the provocation of air passage narrowing and/or the induction of sputum |
Publications (2)
Publication Number | Publication Date |
---|---|
FR11C0002I1 FR11C0002I1 (en) | 2011-01-25 |
FR11C0002I2 true FR11C0002I2 (en) | 2016-03-25 |
Family
ID=3778730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR11C0002C Active FR11C0002I2 (en) | 1994-02-25 | 2011-01-21 | POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT |
Country Status (15)
Country | Link |
---|---|
US (1) | US5817028A (en) |
EP (1) | EP0748228B8 (en) |
JP (7) | JP3979660B2 (en) |
KR (1) | KR100385675B1 (en) |
CN (1) | CN1075737C (en) |
AT (1) | ATE474583T1 (en) |
AU (2) | AUPM411494A0 (en) |
CA (1) | CA2183471C (en) |
DE (2) | DE122011000004I1 (en) |
DK (1) | DK0748228T3 (en) |
ES (1) | ES2349027T3 (en) |
FR (1) | FR11C0002I2 (en) |
NZ (1) | NZ281522A (en) |
PT (1) | PT748228E (en) |
WO (1) | WO1995022993A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5747002A (en) * | 1995-04-05 | 1998-05-05 | Genentech, Inc. | Preparation of sodium chloride aerosol formulations |
DK0902777T4 (en) | 1996-04-16 | 2004-10-11 | Takeda Chemical Industries Ltd | D-mannitol and its preparation |
US6235947B1 (en) * | 1997-04-14 | 2001-05-22 | Takeda Chemical Industries, Ltd. | D-mannitol and its preparation |
US7992572B2 (en) | 1998-06-10 | 2011-08-09 | Asthmatx, Inc. | Methods of evaluating individuals having reversible obstructive pulmonary disease |
US6634363B1 (en) | 1997-04-07 | 2003-10-21 | Broncus Technologies, Inc. | Methods of treating lungs having reversible obstructive pulmonary disease |
US7027869B2 (en) | 1998-01-07 | 2006-04-11 | Asthmatx, Inc. | Method for treating an asthma attack |
US5881720A (en) * | 1997-04-29 | 1999-03-16 | The Procter & Gamble Company | Method of delivering halotherapy |
US6339075B1 (en) | 1997-06-30 | 2002-01-15 | The University Of British Columbia | Use of dextran and other polysaccharides to improve mucus clearance |
US7921855B2 (en) | 1998-01-07 | 2011-04-12 | Asthmatx, Inc. | Method for treating an asthma attack |
US8181656B2 (en) | 1998-06-10 | 2012-05-22 | Asthmatx, Inc. | Methods for treating airways |
US7198635B2 (en) | 2000-10-17 | 2007-04-03 | Asthmatx, Inc. | Modification of airways by application of energy |
GB9826284D0 (en) * | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
JP2002532520A (en) * | 1998-12-22 | 2002-10-02 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Compounds and methods for airway disease treatment and airway drug delivery |
US6926911B1 (en) * | 1998-12-22 | 2005-08-09 | The University Of North Carolina At Chapel Hill | Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs |
AU772798B2 (en) | 1999-04-21 | 2004-05-06 | 1355540 Ontario Inc. | Formulations for detecting asthma |
WO2001062264A2 (en) * | 2000-02-23 | 2001-08-30 | The Procter & Gamble Company | Halotherapy method by inhalation of sodium chloride |
US8251070B2 (en) | 2000-03-27 | 2012-08-28 | Asthmatx, Inc. | Methods for treating airways |
GB0014898D0 (en) * | 2000-06-19 | 2000-08-09 | Innovata Biomed Ltd | Delivery system |
US7104987B2 (en) | 2000-10-17 | 2006-09-12 | Asthmatx, Inc. | Control system and process for application of energy to airway walls and other mediums |
US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
WO2003092654A1 (en) * | 2002-05-02 | 2003-11-13 | President And Fellows Of Harvard College | Formulations limiting spread of pulmonary infections |
US20040226556A1 (en) | 2003-05-13 | 2004-11-18 | Deem Mark E. | Apparatus for treating asthma using neurotoxin |
US20050207983A1 (en) * | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
EP2308469A1 (en) * | 2005-05-18 | 2011-04-13 | Pulmatrix, Inc. | Formulations for alteration of biophysical properties of mucosal lining |
AR062742A1 (en) * | 2006-09-07 | 2008-12-03 | Johnson Michael R | HYDRATION OF THE MUCOSA AND DEPURATION OF THE MUCOSA INCREASED BY TREATMENT WITH BLOCKERS OF SODIUM CHANNELS AND OSMOLITES |
CA2663041A1 (en) * | 2006-09-07 | 2008-03-13 | Parion Sciences, Inc. | Method of enhancing mucosal hydration and mucosal clearance by treatment with sodium channel blockers and osmolytes |
US8714153B2 (en) * | 2007-04-16 | 2014-05-06 | Ric Investments, Llc | Method for selecting a device adapted to treat disordered breathing |
AU2008310734B2 (en) | 2007-10-10 | 2014-06-05 | Parion Sciences, Inc. | Delivering osmolytes by nasal cannula |
US8483831B1 (en) | 2008-02-15 | 2013-07-09 | Holaira, Inc. | System and method for bronchial dilation |
JP5611844B2 (en) | 2008-02-26 | 2014-10-22 | パリオン・サイエンシィズ・インコーポレーテッド | Polycyclic aromatic sodium channel blockers |
ES2398052T5 (en) | 2008-05-09 | 2021-10-25 | Nuvaira Inc | Systems for treating a bronchial tree |
RU2577698C2 (en) | 2009-03-26 | 2016-03-20 | Пулмэтрикс, Инк. | Dry powder formulations and methods of treating pulmonary diseases |
EP2926757B1 (en) | 2009-10-27 | 2023-01-25 | Nuvaira, Inc. | Delivery devices with coolable energy emitting assemblies |
MD4039C1 (en) * | 2009-11-05 | 2010-12-31 | Институт Химии Академии Наук Молдовы | Surface artificial microsalt mine |
US8911439B2 (en) | 2009-11-11 | 2014-12-16 | Holaira, Inc. | Non-invasive and minimally invasive denervation methods and systems for performing the same |
CN106618731B (en) | 2009-11-11 | 2020-08-07 | 努瓦拉公司 | Systems, devices, and methods for treating tissue and controlling stenosis |
MD4089C1 (en) * | 2009-11-18 | 2011-08-31 | Институт Химии Академии Наук Молдовы | Artificial surface halochamber |
MD4040C1 (en) * | 2009-12-09 | 2010-12-31 | Институт Химии Академии Наук Молдовы | Surface artificial halochamber |
EP2464346A1 (en) | 2010-08-30 | 2012-06-20 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
JP5877201B2 (en) | 2010-08-30 | 2016-03-02 | パルマトリックス,インコーポレイテッド | Dry powder formulation and method for treating lung disease |
DK2621488T3 (en) | 2010-09-29 | 2019-03-04 | Pulmatrix Operating Co Inc | CATIONIC DRY POWDER |
CN103228273B (en) | 2010-09-29 | 2017-04-05 | 普马特里克斯营业公司 | Monovalent metal cation dry powder doses are used in suction |
US8945605B2 (en) | 2011-06-07 | 2015-02-03 | Parion Sciences, Inc. | Aerosol delivery systems, compositions and methods |
AU2012267938B2 (en) * | 2011-06-07 | 2017-05-04 | Parion Sciences, Inc. | Methods of treatment |
AR086745A1 (en) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-DIAMINO-6-CHLORINE-N- (N- (4- (4- (2- (HEXIL (2,3,4,5,6-PENTAHYDROXIHEXIL)) AMINO) ETOXI) PHENYL) BUTIL) CARBAMIMIDOIL) PIRAZINA -2-CARBOXAMIDE |
WO2013003444A1 (en) | 2011-06-27 | 2013-01-03 | Michael Ross Johnson | A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity |
CA2865972C (en) | 2012-02-29 | 2022-01-04 | Pulmatrix, Inc. | Inhalable dry powders |
AU2013267504B2 (en) | 2012-05-29 | 2017-11-02 | Parion Sciences, Inc. | Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases |
EP3868321B1 (en) | 2012-06-04 | 2022-11-16 | Boston Scientific Scimed, Inc. | Systems for treating tissue of a passageway within a body |
EP2877113B1 (en) | 2012-07-24 | 2018-07-25 | Boston Scientific Scimed, Inc. | Electrodes for tissue treatment |
US9272132B2 (en) | 2012-11-02 | 2016-03-01 | Boston Scientific Scimed, Inc. | Medical device for treating airways and related methods of use |
WO2014071372A1 (en) | 2012-11-05 | 2014-05-08 | Boston Scientific Scimed, Inc. | Devices for delivering energy to body lumens |
MX2015007796A (en) | 2012-12-17 | 2015-09-04 | Parion Sciences Inc | Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration. |
NZ709197A (en) | 2012-12-17 | 2020-06-26 | Parion Sciences Inc | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
US9398933B2 (en) | 2012-12-27 | 2016-07-26 | Holaira, Inc. | Methods for improving drug efficacy including a combination of drug administration and nerve modulation |
CA2907566C (en) | 2013-04-01 | 2023-08-22 | Pulmatrix, Inc. | Tiotropium dry powders |
EP3708104A1 (en) | 2013-08-09 | 2020-09-16 | Boston Scientific Scimed, Inc. | Expandable catheter and related methods of manufacture and use |
CN104510726A (en) * | 2013-09-27 | 2015-04-15 | 张金华 | Dry salt powder inhalant for cleaning respiratory tract system |
US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
KR102288656B1 (en) | 2020-12-02 | 2021-08-12 | 순천향대학교 산학협력단 | PCR kit for diagnosis of asthma or exacerbation of asthma and method of providing information for diagnosis of asthma or exacerbation of asthma using the same |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5623936A (en) * | 1979-08-01 | 1981-03-06 | Chest Corp | Measuring apparatus of trachea hypersensitivity |
US4446862A (en) * | 1979-10-30 | 1984-05-08 | Baum Eric A | Breath actuated devices for administering powdered medicaments |
DE3167567D1 (en) * | 1980-06-06 | 1985-01-17 | Fisons Plc | Inhalation device for powdered medicaments |
ES8206980A1 (en) * | 1980-10-30 | 1982-09-01 | Riker Laboratories Inc | Powder inhalation device. |
JPS6168418A (en) * | 1984-09-11 | 1986-04-08 | Kanto Ishi Pharma Co Ltd | Expectorant |
DE3518665C2 (en) * | 1985-05-23 | 1994-03-17 | Hoelter Heinz | Wood filter for generating cleaned and naturally fragrant breathing air |
IT1204826B (en) * | 1986-03-04 | 1989-03-10 | Chiesi Farma Spa | INHALATION PHARMACEUTICAL COMPOSITIONS |
CA1317194C (en) * | 1989-05-31 | 1993-05-04 | Yves Cloutier | Device for specific inhalation challenge, method of use and improved generator of particules |
GB9001635D0 (en) * | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
NL9002706A (en) * | 1990-12-10 | 1992-07-01 | Pharmachemie Bv | Apparatus for use when inhaling powdered materials packaged in rod capsules. |
GB9101592D0 (en) * | 1991-01-24 | 1991-03-06 | Glaxo Group Ltd | Compositions |
AU2746292A (en) * | 1991-10-30 | 1993-05-06 | Kenneth Roy Hanson | Asthma and other allergies cure |
DE4140689B4 (en) * | 1991-12-10 | 2007-11-22 | Boehringer Ingelheim Kg | Inhalable powders and process for their preparation |
SE9203743D0 (en) * | 1992-12-11 | 1992-12-11 | Astra Ab | EFFICIENT USE |
US5507277A (en) * | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5558085A (en) * | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
WO1994017822A1 (en) * | 1993-02-12 | 1994-08-18 | T Cell Sciences, Inc. | PULMONARY ADMINISTRATION OF sCR1 AND OTHER COMPLEMENT INHIBITORY PROTEINS |
US5497763A (en) * | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
GB9408053D0 (en) * | 1994-04-22 | 1994-06-15 | Nat Heart & Lung Inst | Pharmaceutical preparation |
US5509404A (en) * | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
US5522385A (en) * | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
-
1994
- 1994-02-25 AU AUPM4114A patent/AUPM411494A0/en not_active Abandoned
-
1995
- 1995-02-23 EP EP95910331A patent/EP0748228B8/en not_active Expired - Lifetime
- 1995-02-23 AT AT95910331T patent/ATE474583T1/en active
- 1995-02-23 NZ NZ281522A patent/NZ281522A/en not_active IP Right Cessation
- 1995-02-23 CA CA002183471A patent/CA2183471C/en not_active Expired - Lifetime
- 1995-02-23 DE DE122011000004C patent/DE122011000004I1/en active Pending
- 1995-02-23 DK DK95910331.8T patent/DK0748228T3/en active
- 1995-02-23 DE DE69536090T patent/DE69536090D1/en not_active Expired - Lifetime
- 1995-02-23 KR KR1019960704666A patent/KR100385675B1/en not_active IP Right Cessation
- 1995-02-23 JP JP52202195A patent/JP3979660B2/en not_active Expired - Lifetime
- 1995-02-23 WO PCT/AU1995/000086 patent/WO1995022993A1/en active Application Filing
- 1995-02-23 CN CN95191808A patent/CN1075737C/en not_active Expired - Lifetime
- 1995-02-23 US US08/696,987 patent/US5817028A/en not_active Expired - Lifetime
- 1995-02-23 ES ES95910331T patent/ES2349027T3/en not_active Expired - Lifetime
- 1995-02-23 AU AU17482/95A patent/AU682756B2/en not_active Expired
- 1995-02-23 PT PT95910331T patent/PT748228E/en unknown
-
2006
- 2006-11-24 JP JP2006317692A patent/JP2007056039A/en active Pending
- 2006-11-24 JP JP2006317693A patent/JP2007056040A/en active Pending
-
2011
- 2011-01-21 FR FR11C0002C patent/FR11C0002I2/en active Active
- 2011-05-06 JP JP2011103746A patent/JP2011148839A/en active Pending
- 2011-05-06 JP JP2011103747A patent/JP2011148840A/en active Pending
-
2012
- 2012-11-26 JP JP2012257722A patent/JP2013136564A/en active Pending
- 2012-11-26 JP JP2012257721A patent/JP2013049708A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU682756B2 (en) | 1997-10-16 |
KR100385675B1 (en) | 2003-10-10 |
JP3979660B2 (en) | 2007-09-19 |
EP0748228B8 (en) | 2010-08-25 |
JP2011148840A (en) | 2011-08-04 |
CA2183471A1 (en) | 1995-08-31 |
JP2007056040A (en) | 2007-03-08 |
NZ281522A (en) | 1998-09-24 |
JP2013049708A (en) | 2013-03-14 |
ATE474583T1 (en) | 2010-08-15 |
ES2349027T3 (en) | 2010-12-21 |
CN1075737C (en) | 2001-12-05 |
JP2013136564A (en) | 2013-07-11 |
DE122011000004I1 (en) | 2011-05-05 |
DK0748228T3 (en) | 2010-10-11 |
AU1748295A (en) | 1995-09-11 |
JP2011148839A (en) | 2011-08-04 |
FR11C0002I1 (en) | 2011-01-25 |
AUPM411494A0 (en) | 1994-03-24 |
WO1995022993A1 (en) | 1995-08-31 |
EP0748228A4 (en) | 1999-12-22 |
CA2183471C (en) | 2008-07-29 |
EP0748228B1 (en) | 2010-07-21 |
JPH10501790A (en) | 1998-02-17 |
JP2007056039A (en) | 2007-03-08 |
EP0748228A1 (en) | 1996-12-18 |
CN1142190A (en) | 1997-02-05 |
US5817028A (en) | 1998-10-06 |
PT748228E (en) | 2010-09-15 |
DE69536090D1 (en) | 2010-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR11C0002I2 (en) | POWDER TO INDUCE THE NARROWING OF THE AIRWAYS AND/OR THE PRODUCTION OF SPUT | |
Fubini et al. | Chemical aspects of the toxicity of inhaled mineral dusts | |
Anderson | History of aerosol therapy: liquid nebulization to MDIs to DPIs | |
Broday et al. | Growth and deposition of hygroscopic particulate matter in the human lungs | |
Castranova et al. | Augmentation of pulmonary reactions to quartz inhalation by trace amounts of iron-containing particles. | |
Sturm | Deposition and cellular interaction of cancer‐inducing particles in the human respiratory tract: Theoretical approaches and experimental data | |
Brand et al. | Aerosol bolus dispersion in healthy subjects | |
Gardner et al. | Toxicology of the Lung | |
Adamis et al. | In vitro and in vivo tests for determination of the pathogenicity of quartz, diatomaceous earth, mordenite and clinoptilolite | |
Lemen | Chrysotile asbestos as a cause of mesothelioma: application of the Hill causation model | |
SCHEUCH et al. | An approach to deposition and clearance measurements in human airways | |
Yao et al. | An overlooked route of inhalation exposure to tap water constituents for children and adults: Aerosolized aqueous minerals from ultrasonic humidifiers | |
Duan et al. | Measuring the administered dose of particles on the facial mucosa of a realistic human model | |
Li et al. | Wearing time and respiratory volume affect the filtration efficiency of masks against aerosols at different sizes | |
CN101466436A (en) | Diagnostic device for determining particle production | |
CN205786347U (en) | A kind of formaldehyde fast quantification kit | |
Chan et al. | Regional deposition of nebulized hypodense nonisotonic solutions in the human respiratory tract | |
Lay et al. | Effects of inhaled iron oxide particles on alveolar epithelial permeability in normal subjects | |
Martonen et al. | Comments on recent data for particle deposition in human nasal passages | |
MY115838A (en) | Method and device for the provocation of air passage narrowing and/or the induction of sputum | |
Polatli et al. | Perlite exposure and 4-year change in lung function | |
Hinds | The lung and the environment | |
Sankhala et al. | Factors that affect the lung deposition | |
Hesbert et al. | Interdependence of polymorphonuclear neutrophils and macrophages stained for N-acetyl-β-glucos-aminidase in lavage effluents from toluene diisocyanate-exposed rat lungs | |
Kilburn | Asbestos and other fibers |